外周血nCD64指数、mHLA-DR及CD14单核细胞百分比在新型冠状病毒肺炎患者不同感染状态下的预后价值

Prognostic Value of Peripheral Blood nCD64 Index, mHLA-DR, and CD14monocyte Percentage in Different Infection Status in COVID-19 Patients.

作者信息

Zhu Mingli, Cheng Jianghao, He Lingyan, Li Chaodan, Shi Bin, Jin Meitong, Yu Jianhua, Huang Jinsong

机构信息

Open Laboratory, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People's Republic of China.

Laboratory Medicine, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, People's Republic of China.

出版信息

J Inflamm Res. 2025 Jul 29;18:10099-10110. doi: 10.2147/JIR.S519226. eCollection 2025.

DOI:10.2147/JIR.S519226

PMID:40761384

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12319155/

Abstract

OBJECTIVE

To explore the value of the neutrophil CD64 (nCD64) index, monocytic HLA-DR (mHLA-DR), and the percentage of CD14 monocytes in the prognosis of Coronavirus disease 2019 (COVID-19).

METHODS

Fifty-seven COVID-19 patients from December 2022 to November 2023 were divided into two groups: non-severe group (mild or moderate cases) and severe group (severe or critical cases). Among them, 17 patients were deceased. Flow cytometry was employed to detect the levels of nCD64 index, mHLA-DR, and CD14monocyte percentage in blood. The receiver operating characteristic (ROC) curve was used to evaluate the predictive value of mHLA-DR, nCD64 index, and CD14 monocyte percentage for COVID-19 prognosis.

RESULTS

The expression levels of mHLA-DR and the percentage of CD14 monocytes in non-severe COVID-19 patients were significantly higher than those in severe and deceased patients ( < 0.05). In contrast, the nCD64 index in non-severe patients was significantly lower than that in severe and deceased patients (< 0.05). The expression level of mHLA-DR and the percentage of CD14 monocytes in deceased patients were significantly lower than those in surviving patients (<0.001), while the nCD64 index level in surviving patients was significantly lower than that in deceased patients (<0.001). The area under the curve (AUC) for the nCD64 index, mHLA-DR and the percentage of CD14 monocytes were 0.850, 0.779 and 0.871, respectively. Patients with CD14 monocyte percentage > 4.9%, mHLA-DR value >16720.5, and nCD64 index <5.87 had a good prognosis value ( < 0.05).

CONCLUSION

The nCD64 index, mHLA-DR level, and percentage of CD14 monocytes may serve as biomarkers for predicting clinical outcomes in COVID-19 patients.

摘要

目的

探讨中性粒细胞CD64（nCD64）指数、单核细胞人类白细胞抗原DR（mHLA-DR）及CD14单核细胞百分比在2019冠状病毒病（COVID-19）预后中的价值。

方法

选取2022年12月至2023年11月的57例COVID-19患者，分为两组：非重症组（轻症或中症病例）和重症组（重症或危重症病例）。其中17例患者死亡。采用流式细胞术检测血液中nCD64指数、mHLA-DR水平及CD14单核细胞百分比。采用受试者工作特征（ROC）曲线评估mHLA-DR、nCD64指数及CD14单核细胞百分比对COVID-19预后的预测价值。

结果

非重症COVID-19患者的mHLA-DR表达水平及CD14单核细胞百分比显著高于重症及死亡患者（P<0.05）。相反，非重症患者的nCD64指数显著低于重症及死亡患者（P<0.05）。死亡患者的mHLA-DR表达水平及CD14单核细胞百分比显著低于存活患者（P<0.001），而存活患者的nCD64指数水平显著低于死亡患者（P<0.001）。nCD64指数、mHLA-DR及CD14单核细胞百分比的曲线下面积（AUC）分别为0.850、0.779和0.871。CD14单核细胞百分比>4.9%、mHLA-DR值>16720.5且nCD64指数<5.87的患者具有良好的预后价值（P<0.05）。